Kimberly A. Chianese‐Bullock

Author

Also Known As

K. A. Chianese-Bullock, Kimberly A Chianese-Bullock, Kimberly A Chianese-bullock, Kimberly A. Chianese-Bullock, Kimberly A. Chianese‐Bullock, Kimberly A. Chianese‑Bullock, Kimberly Chianese-Bullock

100

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

University of Virginia University of Virginia Health System Carter Center Fox Chase Cancer Center The University of Texas MD Anderson Cancer Center

About

Kimberly A. Chianese‐Bullock is an author at University of Virginia specializing in immunology, medicine, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	317
2	Immunology	9	9	317
3	Cell Biology	3	3	139
4	Allergy	1	1	24
5	Clinical Immunology	1	1	37

Kimberly A. Chianese‐Bullock

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation David J. Kittlesen, Kimberly A. Chianese‐Bullock, Zhi Q. Yao, Journal of Clinical Investigation	2000	328
Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells Craig L. Slingluff, Gina R. Petroni, Galina V. Yamshchikov, Journal of Clinical Oncology	2003	321
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial Craig L. Slingluff, Gina R. Petroni, Walter C. Olson, Clinical Cancer Research	2009	168
Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting Craig L. Slingluff, Gina R. Petroni, Kimberly A. Chianese‐Bullock, Clinical Cancer Research	2007	160
Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule Craig L. Slingluff, Gina R. Petroni, Galina V. Yamshchikov, Journal of Clinical Oncology	2004	146
MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma Kimberly A. Chianese‐Bullock, Jennifer Pressley, Courtney F. Garbee, The Journal of Immunology	2005	124
Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine Craig L. Slingluff, Gina R. Petroni, Kimberly A. Chianese‐Bullock, Journal of Clinical Oncology	2011	120
Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens Craig L. Slingluff, Gina R. Petroni, Walter C. Olson, Journal of Clinical Oncology	2008	117
A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602) Craig L. Slingluff, Fengmin Zhao, Kimberly A. Chianese‐Bullock, Clinical Cancer Research	2013	115
A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer Kimberly A. Chianese‐Bullock, William P. Irvin, Gina R. Petroni, Journal of Immunotherapy	2008	110

Page 1